About the Company
We do not have any company description for INTENSITY THERAPEUTICS, INC. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on INTENSITY THERAPEUTICS, INC.
Intensity Therapeutics, Inc. Announces the Appointment of ... - Nasdaq
--Intensity Therapeutics, Inc., a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to ...
Intensity Therapeutics, Inc. Announces the Closing and Full ... - Nasdaq
Intensity Therapeutics, Inc. Announces the Closing and Full Exercise of the Over-Allotment Option from its Upsized Initial Public Offering, Raising a Total of $22.425 Million in Gross Proceeds ...
Intensity Therapeutics, Inc. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies ...
Intensity Therapeutics, Inc. to Collaborate with Author, Model ...
SHELTON, Conn., May 28, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), ("Intensity" or "the Company") a late-stage clinical biotechnology company focused on the discovery and ...
Intensity Therapeutics, Inc. Announces that INT230-6 Achieved 100% ...
SHELTON, Conn., June 30, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and ...
Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered ...
Intensity Therapeutics, Inc. (Nasdaq: INTS), ("Intensity" or the "Company") a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based ...
Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin ...
May 15, 2024 8:01 AM ETIntensity Therapeutics, Inc. (INTS) INT230-6, Intensity's lead proprietary investigational product candidate, is designed for direct intratumoral injection. INT230-6 was ...
Intensity Therapeutics, Inc. Appoints Ian B. Walters M.D., MBA as Vice ...
Intensity Therapeutics, Inc. Appoints Ian B. Walters M.D., MBA as Vice President and Chief Medical Officer September 03, 2014 07:36 AM Eastern Daylight Time ...
Intensity Therapeutics, Inc. Announces Proposed Public Offering of ...
SHELTON, Conn., June 11, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the discovery and ...
Intensity Therapeutics, Inc. Raises $6.6 Million from At The ... - KTLA
Intensity Therapeutics, Inc. Raises $6.6 Million from At The Market Offering (ATM) Stock Sales in July 2025 News provided by Intensity Therapeutics Inc. Aug 04, 2025, 7:47 AM ET ...
Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered ...
Intensity Therapeutics, Inc. (Nasdaq: INTS), ("Intensity" or the "Company") a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based ...
Intensity Therapeutics, Inc. Raises $6.6 Million from At The Market ...
Intensity Therapeutics, Inc. Raises $6.6 Million from At The Market Offering (ATM) Stock Sales in July 2025 News provided by Intensity Therapeutics Inc. Aug 04, 2025, 7:47 AM ET ...
Similar Companies
Loading the latest forecasts...